Physician profile
Christopher Michael Roberts
NPI 1205242146
$1,780.37
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $849 · 2022: $641 · 2023: $219 · 2024: $70.76.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $290.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $290.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $502.75 | 2021-2023 | |
| Janssen Biotech, INC. | $369.25 | 2021-2022 | |
| Leo Pharma INC. | $166.27 | 2021-2023 | Adbry |
| Regeneron Healthcare Solutions, INC. | $141.59 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $108.79 | 2022-2024 | |
| Vyne Pharmaceuticals INC. | $71.93 | 2021 | |
| Amgen INC. | $54.95 | 2022 | |
| Ucb, INC. | $50.07 | 2022-2023 | Cimzia |
| Pfizer INC. | $48.16 | 2022 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $47.87 | 2021 | |
| Sun Pharmaceutical Industries INC. | $43.86 | 2021-2022 | |
| Genzyme Corporation | $40.89 | 2021-2022 | |
| Incyte Corporation | $38.99 | 2022 | |
| Biofrontera INC. | $36.70 | 2021-2023 | Ameluz, Xepi, Bf-Rhodoled |
| Lilly USA, LLC | $30.25 | 2021-2022 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Verrica Pharmaceuticals INC. | $28.05 | 2023 | Ycanth |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Roberts listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.